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Abstract
Nitric oxide (NO) is an important physiological mediator that regulates a wide range of 
cellular processes in many tissues. Therefore, the accurate and reliable measurement of 
physiological NO concentration is essential to the understanding of NO signaling and its 
biological role. Most methods used for NO detection are indirect including spectroscopic 
approaches such as the Griess assay for nitrite and detection of methemoglobin after 
NO reaction with oxyhemoglobin. These methods cannot accurately reflect the changes 
in NO concentration in vivo and in real time. Therefore, direct methods are necessary 
for investigating biological process and diseases related to NO in biological conditions. 
There is a growing interest in the development of electrochemically based sensors for 
direct, in vivo, and real-time monitoring of NO. Electrochemical methods offer sim-
plicity, good sensitivity, high selectivity, fast response times, and long-term calibration 
stability compared to other techniques including electron paramagnetic resonance, che-
miluminescence, and fluorescence. In this article, we present real-time NO dynamics in 
the myocardium during myocardial ischemia-reperfusion (IR) utilizing electrochemical 
NO microsensor. And applications of electrochemical NO sensor for the evaluation of 
cardioprotective effects of therapeutic treatments such as drug administration and isch-
emic preconditioning are reviewed.
Keywords: nitric oxide, real-time detection, myocardial ischemia-reperfusion, 
electrochemical sensor, therapeutic treatments
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1. Introduction
Nitric oxide (NO) is one of gaseous cellular-signaling molecules, which regulates a wide 
range of physiological and cellular processes in various tissues. In particular, it plays 
a vital role in a variety of biological processes including immune defense, neurotransmis-
sion, regulation of cell death (apoptosis), and cell motility [1–4]. NO has some key fea-
tures that make this molecule suited to its cellular-signaling functions. NO is a lipophilic 
diatomic gas under atmospheric conditions. As it has a relatively small Stokes radius and 
neutral charge, it can rapidly diffuse the cell membrane. The presence of an unpaired 
electron in NO supports its high reactivity with oxygen (O
2
), superoxide (O
2
−), transition 
metals, and thiols [5, 6]. The removal of the unpaired electron in NO generates the nitroso-
nium cation NO+, while the addition of an electron forms the nitroxyl anion (NO−). These 
different forms of NO represent distinct chemical reactivities [6, 7]. And NO reacts with 
O
2
− to form peroxynitrite (OONO−), a particularly destructive molecule within biological 
systems [8].
NO is known to play a major role in vascular biology and heart failure. NO is a double-
edged sword; NO inhibits ischemia-reperfusion (IR) injury, represses inflammation, and 
prevents left ventricular remodeling, whereas excess NO and coexistence of reactive oxygen 
species (ROS) with NO are injurious [6]. In that, low concentration of NO has beneficial 
effects on heart function, while high concentration of NO has opposite effects. Recently, it 
was reported that the final action of NO is not only regulated by its concentration and cel-
lular confinement but also strongly depends on the level of oxidative stress in the myocar-
dium [4]. But, the cardioprotective mechanism of NO is not yet clear, and it is not known 
whether NO effectively acts during ischemia or during reperfusion. Therefore, the accurate 
and quantitative detection of physiological NO concentration is crucial to the understanding 
of NO signaling and its biological role. This review focuses on the role of NO in myocardial 
IR injury. In addition, we will summarize the studies from our laboratory, which evaluates 
the cardioprotective effects of therapeutic treatments such as drug administration and isch-
emic preconditioning in the myocardium during myocardial IR utilizing electrochemical 
NO sensor.
2. Production of nitric oxide
In general, NO is produced from the conversion of L-arginine to L-citrulline, a reaction 
catalyzed by a family of enzymes called NO synthases (NOSs). Endothelial NOS (eNOS, 
also known as NOS3) and neuronal NOS (nNOS, also known as NOS1) are constitutive 
and low-output enzymes, whereas the macrophage-type NOS isoform, known as inducible 
NOS (iNOS, also known as NOS2), is an inducible and high-output enzyme [9]. NOS is 
a homodimeric oxidoreductase containing iron protoporphyrin IX (heme), flavin adenine 
dinucleotide, flavin mononucleotide, and tetrahydrobiopterin (BH
4
), which is a cofactor 
essential for the catalytic activity of all three NOS isoforms [6, 10, 11]. NO biosynthesis 
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by the three NOS isoforms can be suppressed by several small-molecule inhibitors: NG-
methyl-L-arginine (L-NMA) inhibits all NOS isoforms, and L-NG-nitroarginine methyl ester 
(L-NAME) has some selectivity for the constitutive NOS isoforms (i.e., nNOS and eNOS), 
whereas other inhibitors such as aminoguanidine, 1400 W, and many others show selectiv-
ity for iNOS [9].
Although NOS had been generally considered to be the primary source of NO in biological 
systems, nonenzymatic NO synthesis also occurs. NO can be produced in tissues by either 
direct disproportionation or reduction of nitrite to NO under the acidic and highly reduced 
conditions which occur in disease states, such as ischemia [12]. Tissue acidosis occurring 
during ischemia increases NO production independent from eNOS [13], and even at normal 
pH, xanthine oxidase in the presence of low pO
2
 and high nicotinamide adenine dinucleotide 
(NADH) concentration is capable of producing NO from nitrite [14]. Besides, in the isolated 
rat heart [15] and in rabbit hindlimb muscle [16], the NO concentration is still increased dur-
ing ischemia after complete NOS inhibition by Nw-nitro-L-arginine (L-NNA).
3. Nitric oxide measurements
It is difficult to directly measure NO concentration in vivo because NO is present at nano-
molar concentrations in the body and highly reactive with numerous endogenous species 
including free radicals, oxygen, peroxides, transition metals, and metalloproteins. Indeed, the 
half-life of NO in biological milieu is <10 s [17].
3.1. Indirect method (Griess assay)
Indirect methods measure the stable metabolites of NO such as nitrites (NO
2
−) and nitrates 
(NO
3
−). The most widely used method for NO detection is based on Griess assay reagents, 
which can react with nitrite to form a purple azo dye. This method requires that nitrate 
first be reduced to nitrite and then nitrite determined by the Griess reaction [18]. Briefly, 
the Griess reaction is a two-step diazotization reaction. First, the NO-derived nitrosating 
agent, dinitrogen trioxide (N
2
O
3
), generated from the acid-catalyzed formation of nitrous 
acid from nitrite (or autoxidation of NO) reacts with sulfanilamide to produce a diazo-
nium ion. And then it is coupled to N-(1-napthyl)ethylenediamine to form a chromophoric 
azo product that strongly absorbs at 540 nm [19]. This method has some disadvantages 
including its sensitivity and its ability to detect nitrate. Therefore, nitrate must be con-
verted to nitrite before the total nitrite is detected. The reduction of nitrate to nitrite can 
be achieved by using bacterial nitrate reductase or reducing metal such as cadmium [20]. 
However, these methods often fail to accurately reflect the spatial and temporal distribu-
tions of NO in biological environments. In addition, the concentration of nitrate and nitrite 
metabolite may not show the accurate amount of NO in the specific site because other 
parts of the body can also produce these compounds. Therefore, direct measurement strat-
egies are necessary for investigating the physiological origin and action of endogenously 
produced NO.
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3.2. Direct methods (nitric oxide sensor)
Several methods exist for directly measuring NO including electron paramagnetic resonance 
spectroscopy [21], chemiluminescence [22], fluorescence [23, 24], and electrochemical sens-
ing [17, 25, 26]. Of these approaches, miniaturized electrochemical (e.g., amperometric and 
voltammetric) sensors represent the most promising means for determining the spatial and 
temporal distributions of NO near its physiological source [17]. Electrochemical methods pro-
vide simplicity, fast response times, good sensitivity, high selectivity, and long-term calibra-
tion stability [27, 28]. The most simple detection scheme to date involves the electrochemical 
oxidation of NO at a metal (e.g., platinum and gold) or carbon electrode [27, 29]. However, 
it is necessary to use a relatively high working potential (+0.7 to +0.9 V vs. Ag/AgCl) for the 
direct electrooxidation of NO. In this condition, several interferences from other readily oxi-
dizable biological species such as nitrite, ascorbic acid, uric acid, and acetaminophen often 
disturb selective detection of NO [25, 27]. Therefore, further surface modification with perm-
selective membranes is required to achieve the desired selectivity for NO via size exclusion 
or electrostatic repulsion [4]. Indeed, several polymeric materials have been evaluated as gas-
permeable or permselective membranes including nafion, collodion, polycarbazole, o- and 
m-phenylenediamine, poly(tetrafluoroethylene), cellulose acetate, and multilayer hybrids of 
these polymers [27, 30–36]. In particular, Shin et al. reported that sol-gel-derived electrochem-
ical sensors showed good sensitivity and selectivity for NO detection [17, 27].
4. Nitric oxide in myocardial ischemia-reperfusion injury
Myocardial infarction (MI) is one of the major causes of morbidity and mortality in indus-
trialized countries, despite the improvement in clinical management of the disease. MI is 
caused by sudden stoppage of blood supply to the heart that leads to tissue necrosis. The 
normal myocardium produces more than 90% of its adenosine triphosphate (ATP) by oxi-
dative metabolism and less than 10% by anaerobic glycolysis [4, 37]. After the induction of 
ischemia, the myocardium can be completely recovered to its normal state if blood supply is 
adequately restored. But cellular necrosis eventually occurs if ischemia persists [4]. During 
severe cardiac ischemia, cardiac myocytes must drastically reduce ATP demand or utiliza-
tion to meet the needs for survival and thus balance the reduced ATP supply with reduced 
demand during severe ischemia [4, 38].
NO has been extensively studied in the setting of myocardial IR injury. Previous studies dem-
onstrate that the deficiency of eNOS deteriorates myocardial IR injury [39], whereas the over-
expression of eNOS [40], the administration of NO donors [41], and inhaled NO gas therapy 
[42] significantly protect the myocardium. NO possesses several physiological properties that 
make it a potent cardioprotective-signaling molecule, as follows [43]: First, NO is a potent 
vasodilator in the ischemic myocardium which enables an essential perfusion of injured tissue. 
Second, NO reversibly inhibits mitochondrial respiration during early reperfusion. It leads to 
a decrease in mitochondrial-driven injury by extending the zone of adequate tissue cellular 
oxygenation away from vessels [43–45]. It is known that restoration of oxygen at reperfusion 
Nitric Oxide Synthase - Simple Enzyme-Complex Roles76
leads to a lethal burst of reactive oxygen species (ROS) generation. An important source of ROS 
is the mitochondria. In mitochondria, electrons from intermediary metabolism move down the 
electron transport chain (ETC) and transferred to oxygen at complex IV [46]. When oxygen-
ation is normal, complex I activity is high because a cysteine residue on its ND3 subunit is pro-
tected from modification. During ischemia (without oxygen), electrons accumulate along the 
ETC [46]. Reperfusion leads to a burst of ROS production from multiple sites which can attack 
proteins, lipids, and DNA, as well as lethal activation of the mitochondrial permeability tran-
sition pore [46]. NO inhibits mitochondrial complex I by S-nitrosation (or S-nitrosylation) of 
cysteines, which subsequently prevents damage during IR injury [47]. Reversible S-nitrosation 
of complex I slows the reactivation of mitochondria during the crucial first minutes of the 
reperfusion, thereby decreasing ROS production, oxidative damage, and tissue necrosis [48]. 
Third, NO is a potent inhibitor of neutrophil adherence to the vascular endothelium which is a 
significant event initiating further leukocyte activation and superoxide radical production [43, 
49, 50]. Fourth, NO prevents platelet aggregation [51], and this effect attenuates capillary plug-
ging together with the anti-neutrophil actions of NO [52]. Finally, NO inhibits apoptosis either 
directly or indirectly by inhibiting caspase-3-like activation via a cGMP-dependent mecha-
nism [43, 53] and by direct inhibition of caspase-3-like activity through protein S-nitrosylation 
[43, 54]. In summary, the release of low concentrations of NO by constitutive NOS played a 
role in the regulation of coronary blood flow, inhibition of platelet aggregation, adherence to 
the endothelium, and possibly modulation of myocardial oxygen consumption.
But, excessive generation of NO is detrimental to cardiovascular function as exemplified in 
septic shock where burst generation of iNOS-derived NO causes hypotension, cardiodepres-
sion, and vascular hyporeactivity [55]. The detrimental effect of excess NO is attributed to 
the action on mitochondria. NO inhibits the mitochondrial respiratory chain, resulting in 
inhibition of ATP production, increased oxidant production, and increased susceptibility to 
cell death [56]. Inhibition of mitochondrial respiration by NO and its derivatives stimulates 
production of reactive oxygen and nitrogen species by mitochondria [56], which contribute 
to cell death in excess.
In conclusion, NO can preserve blood flow in the ischemic tissues and reduce platelet aggre-
gation and neutrophil-endothelium interaction following IR. Besides, low concentrations of 
NO improve cardiomyocyte function. On the contrary, higher NO concentrations diminish 
cardiomyocyte function, mediate inflammatory processes following IR, worsen mitochondrial 
respiration, and even induce cardiomyocyte death. Therefore, it seems that NO can mediate 
both protective and detrimental myocardial effects which are crucially dependent upon the 
experimental conditions. Consensus is being reached in the debate regarding a NO protective 
effect, with most studies reporting its protective effects. However, the role of their product, 
NO, in the process of IR is still not well defined mainly because of the difficulty in measuring 
NO concentration in the body tissue.
In the next section, we summarize real-time NO dynamics in the myocardium during myo-
cardial IR. And applications of electrochemical NO sensor for the evaluation of cardioprotec-
tive effects of therapeutic treatments such as hypothermia, drug administration, and ischemic 
preconditioning are summarized.
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5. Real-time monitoring of nitric oxide dynamics in the myocardium 
during myocardial ischemia-reperfusion
5.1. Hypothermia
In general, hypothermia is thought to reduce the metabolic needs of cells, specifically per-
haps by reducing the oxygen demand in the hypothermic tissues [57]. Besides, in isolated 
heart perfusion system, hearts were placed in ice-cold buffer as quickly as possible to avoid 
any detrimental effects of hypoxia. Therefore, myocardial hypothermia might be a useful 
technique to limit ischemic damage during infarction or as adjunctive therapy during min-
imally invasive cardiac surgery [58]. Lee et al. reported changes in NO dynamics during 
myocardial IR utilizing a sol-gel-modified electrochemical NO sensor and isolated heart per-
fusion system [4]. They attempted to clarify the role of endogenous NO release by comparing 
intact and cardioprotected hearts, in which cardioprotection was conferred by hypothermic 
treatment of the hearts. For the hypothermic group, hearts were immediately immersed in 
ice-cold perfusion buffer for 3 min after harvest. In the ischemic myocardium, NO showed a 
time-dependent change during the 40 min ischemic episode. After myocardial ischemia and 
early reperfusion, the restoration level of NO was decreased below the pre-ischemic level 
(Figure 1). However, the myocardium with hypothermic treatment (151 ± 37 nM) generated 
more NO during the ischemic period than that without any treatment (59 ± 15 nM). Besides, 
the restoration level of NO in the hypothermic group (−57 ± 26 nM) was significantly higher 
than that of the intact group (−170 ± 50 nM, p < 0.05) [4]. As a result, they inferred that hypo-
thermic treatment of the heart would promote endogenous NO production in the ischemic 
myocardium. It might be a helpful therapeutic strategy for protecting the myocardium from 
IR injury [4].
5.2. Myocardial oxygen dynamics
Because oxygen plays a critical role in the pathophysiology of myocardial injury during sub-
sequent reperfusion, as well as ischemia, the accurate measurement of myocardial oxygen 
tension is crucial for the assessment of myocardial viability by IR injury. Lee et al. reported 
a sol-gel-derived electrochemical oxygen microsensor to monitor changes in oxygen tension 
(pO
2
) during myocardial IR [59]. And they analyzed differences in oxygen tension recovery 
in the post-ischemic myocardium depending on ischemic time to investigate the correlation 
between recovery parameters for oxygen tension and the severity of IR injury. Figure 2 shows 
the nine parameters for pO
2
 dynamics during myocardial IR and the maximum and restora-
tion values of pO
2
 at different ischemic times. As a result, they observed that if ischemia was 
stopped within 20 min, the pO
2
 in the myocardium after the onset of reperfusion restored to 
pre-ischemic levels. However, the pO
2
 in the myocardium did not recover to its pre-ischemic 
state, if the ischemic time was >30 min [59]. These results show that the maximum and resto-
ration values of pO
2
 in the post-ischemic myocardium were closely related to the infarct size 
[59]. In summary, they demonstrated that the degree of reoxygenation in the post-ischemic 
myocardium was an important index of IR injury and myocardial viability, utilizing a sol-gel-
derived electrochemical oxygen microsensor and recovery parameters.
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Figure 1. Representative real-time measurement of NO in intact (A) and hypothermic (B) groups during myocardial 
ischemia-reperfusion of Langendorff-perfused rat hearts. Reproduced with permission from Lee et al. [4]. © 2011 
Elsevier B.V.
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5.3. Remote ischemic preconditioning
Ischemic preconditioning is an adaptive response of briefly ischemic tissues that serves to protect 
against subsequent prolonged ischemic insults and reperfusion injury [60]. In particular, remote 
ischemic preconditioning (RIPC) is a novel method where ischemia followed by reperfusion of 
one organ is believed to protect remote organs either by the release of biochemical messengers 
into circulation or by the activation of nerve pathways, resulting in the release of messengers that 
have a protective effect [60–62]. This preserves the target tissue without trauma to major vessels or 
direct stress to the target organ [63]. Although some studies have demonstrated that endothelial 
NO is one of the major contributors to the candidate mechanism of RIPC [60, 64], the mechanism 
of RIPC-induced cardioprotection has not yet been fully elucidated. Lee et al. simultaneously mea-
sured NO and O
2
 dynamics in the myocardium during myocardial IR utilizing sol-gel-modified 
electrochemical NO and O
2
 microsensors [65]. By comparing control and RIPC-treated hearts, we 
attempted to clarify the correlation between NO release in the ischemic period and O
2
 restoration 
in the myocardium after reperfusion. Figure 3 represents the schematic diagrams of experimental 
design and experimental setup of an isolated heart perfusion system and a real-time monitoring 
system for NO and oxygen tension dynamics during myocardial IR of the rat.
Figure 2. (A) Definition of analysis parameters proposed for changes in oxygen tension throughout the experimental 
protocol and box and whisker graph depicting maximum (B) and restoration levels (C) of oxygen tension during the 
reperfusion period as a percentage of pre-ischemic levels at different ischemic times (n = 3 per group). Reproduced from 
Lee et al. [59]. © The Royal Society of Chemistry 2012.
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As a result, the concentration change of NO in the RIPC group was different from those 
in the control group during the ischemic period. In the control group, the NO level ini-
tially declined but then gradually inclined during the ischemic episode. In contrast, the 
NO level in the RIPC group rapidly increased after the onset of ischemia and continued 
to rise throughout the entire ischemic period [65]. When reperfusion was initiated, the 
pattern of both NO level and pO
2
 in the RIPC group was different from that of the control 
group. As a result, the NO level and the pO
2
 of the myocardium in the RIPC group were 
Figure 3. Schematic diagrams of (A) experimental design and (B) experimental setup of an isolated heart perfusion 
system and a real-time monitoring system for nitric oxide and oxygen tension dynamics during myocardial ischemia-
reperfusion of the rat. Reproduced from Kang et al. [65]. © 2013 Elsevier B.V.
Real-Time Monitoring of Nitric Oxide Dynamics in the Myocardium: Biomedical Application of Nitric Oxide Sensor
http://dx.doi.org/10.5772/67255
81
restored to pre-ischemic levels, unlike those in the control group that did not recover to 
their pre-ischemic state (Figures 4 and 5). In summary, the endogenous production of NO 
during the ischemic period appears to be correlated with the restoration of NO and pO
2
 in 
the post-ischemic myocardium after early reperfusion. Additionally, RIPC would promote 
endogenous NO release against ischemic stimuli and subsequently facilitate reoxygen-
ation in post-ischemic myocardia after reperfusion [65].
5.4. Effect of prostaglandin E1
Prostaglandin E1 (Alprostadil®, PGE1), which is an important member of the prostaglandin 
(PG) family, is a product of arachidonic acid metabolism by cyclooxygenase [66, 67]. Similar 
to NO, PGE1 has cardioprotective effects during IR [67, 68], as well as vasodilator effects on 
the systemic and pulmonary circulation [69]. Fang et al. reported that pretreatment of human 
umbilical vein endothelial cells with PGE1 significantly protected those cells from H
2
O
2
-
induced cell death [66]. And this effect might depend, at least in part, on the upregulation of 
NO expression [66]. On the other hand, Huk et al. reported that PGE1 prevents the excessive 
generation of NO, superoxide, and ONOO− which trigger a cascade of events leading to IR 
injury [70]. Though it is known that PGE1 has cardioprotective effects against IR injury, its 
mechanism and the correlation between NO and PGE1 are not yet clear. Lee et al. monitored 
the changes in NO and O
2
 levels in the myocardium during myocardial IR that were induced 
by PGE1 pretreatment, utilizing sol-gel-modified amperometric NO and O
2
 microsensors 
[67]. They investigated the correlation between endogenous NO and PGE1 in the ischemic 
episode, as well as oxygen recovery in the post-ischemic myocardium [67]. For statistical and 
quantitative analysis, they utilized analytical parameters such as %NO and %pO
2
, which are 
defined as the percentage of normalized NO (Eq. (1)) and pO
2
 (Eq. (2)), respectively:
Figure 4. Representative real-time and simultaneous measurement of nitric oxide and oxygen tension in (A) control and 
(B) remote ischemic preconditioning (RIPC) groups during myocardial ischemia-reperfusion in Langendorff-perfused 
rat hearts. Reproduced from Kang et al. [65]. © 2013 Elsevier B.V.
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   %NO =  NO level on ischemic or reperfusion period  (nM)     ________________________________________________________________________   
NO level on pre‐ischemic period  (mM) 
 × 100 (1)
   % pO 
2
  =   pO 2  level on ischemic or reperfusion period  (mmHg)     __________________________________________________________________________   
 pO 
2
  level on pre‐ischemic period  (mmHg)  × 100 (2)
As a result, there were significant differences in the NO dynamics during ischemia and reper-
fusion between the control and PGE1-treated rat hearts (Table 1 and Figure 6) as follows 
Figure 5. The correlation between ischemia-evoked nitric oxide concentration and reoxygenation parameters of the post-
ischemic myocardium in two groups. Error bars represent standard deviation of the mean (n = 5 per group). Reproduced 
from Ref. [65], Kang SW et al., Anal. Chim. Acta 802, 74 (2013). © 2013 Elsevier B.V.
Real-Time Monitoring of Nitric Oxide Dynamics in the Myocardium: Biomedical Application of Nitric Oxide Sensor
http://dx.doi.org/10.5772/67255
83
[67]: In the control group, the initial decrease in %NO was 56.0 ± 12.9, and the maximum NO 
level was 86.7 ± 18.5 during the ischemic period. However, in the PGE1 group, %NO rapidly 
declined to 19.9 ± 5.8% of the pre-ischemic levels, and this was maintained throughout the 
30 min ischemic episode. In addition, after the onset of reperfusion, NO level inclined to a 
maximum of 82.0 ± 6.4 but did not exceed the pre-ischemic basal NO level. In the control 
group, the maximum %NO response (164.9 ± 41.0) to reperfusion was approximately double 
than that of the PGE1 group (p < 0.01, n = 5). They suggest that the cardioprotective effect of 
PGE1 might be attributed to a reduction in excessive NO production during early reperfusion.
Figure 6. The correlation between the maximum %NO and restoration %pO
2
 during 60 min of reperfusion in the two 
groups. Error bars represent the standard deviation from the mean (n = 5 per group). Reproduced from Kang et al. [67]. 
© 2014 Elsevier B.V.
 
Parameters Control group (n = 5) PGE1 group (n = 5) p value
Level of baseline during pre-ischemic period 101.4 ± 0.9 101.0 ± 2.9 0.767
Level of initial decrement after the onset of 
ischemia
56.0 ± 12.9 19.9 ± 5.8 <0.001
Maximum level during ischemia 86.7 ± 18.5 26.0 ± 13.1 <0.001
Maximum level during the reperfusion period 164.9 ± 41.0 82.0 ± 6.4 0.01
Restoration level after 60 min of reperfusion 98.7 ± 42.1 45.6 ± 10.1 0.046
Reproduced from Ref. [67], Kang et al., Sensor. Actuat. B – Chem. 203, 245 (2014). © 2014 Elsevier B.V.
Table 1. Changes in %NO level during myocardial ischemia-reperfusion of the control and PGE1-treated groups.
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6. Conclusions
NO plays important roles in the cardiovascular system by mediating various physiologi-
cal and pathophysiological processes. From the real-time measurement of endogenous NO 
dynamics in the myocardium, we summarize as follows: (1) NO concentration was definitely 
decreased after myocardial ischemia; (2) there was endogenous NO formation as a protec-
tive response against ischemia during the ischemic episode, but it was not enough to restore 
pre-ischemic NO level; (3) the promotion of endogenous formation and inhibition of the time-
course alteration of NO during an ischemic episode might be helpful as a therapeutic strategy 
for protecting the myocardium from ischemic injury; and (4) the reduction of excessive NO 
production in early reperfusion period might also be helpful as a therapeutic strategy to pro-
tect the myocardium from IR injury. And NO permselective microsensors have good sensitiv-
ity and specificity for detecting biologically released NO dynamics in vivo and can be applied 
in real-time monitoring of NO dynamics in various organs.
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